Tagged with ase

Asia-Pacific Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical and regulated way. ChongXiang Tan, Fengyun (Vicky) Han and Annetta C. Beauregard of Janssen Pharmaceutical Companies of Johnson & Johnson…

Germany A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the rare kidney disease immunoglobulin A nephropathy (IgAN).   Bayer’s hunt…

ASEAN Takeda’s Soon Yee Chow and Helene Sou, writing in the September 2022 edition of DIA’s Global Forum magazine, outline how digitalisation initiatives, if properly enacted, can help the ASEAN region achieve its vision of a free-trade market for high-quality and safe drugs across member states.   One key pillar of…

Americas Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities in specialty care, and the company’s strategy to continue a decades-long legacy. With many new governments in the region, we…

Spain Sanofí’s general manager for Spain, Margarita Lopez Acosta, comments on the company’s “Play to Win” strategy, the presence of the French giant in Spain and the leading role of the country in clinical trials. She also explains possible solutions to the challenges around access to innovation in Spain.  Both the…

Italy Dompé’s Chief Operating Officer, Eriona Gjinukaj, responsible for creating the Italian mid-cap’s US affiliate, reveals the challenges and rewards of that experience and explains how she saw the company go from a primary care-focused Italian company to an internatonal biotech with an EMA and FDA-approved breakthrough therapy. I was lucky…

Spain After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any other region. The birthplace of many of the country’s pharma success stories, Catalonia boasts a strong scientific output by European…

USA Monica Weldon draws on her own experience as a rare disease patient advocacy group CEO to outline how such groups can work collaboratively with other stakeholders in drug development to better target funding and create a more patient-centric drug development process that ultimately gets better drugs to rare disease patients…

Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…

Europe In Europe, patient access to Orphan Medicinal Products (OMP) for the treatment of rare diseases remains inequitable. With the common goal of ensuring broader and faster access to OMPs across Europe, EURORDIS and EFPIA have joined forces to propose a series of solutions. According to a 2020 study, fragmentation of…

Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives.  Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…

Asia-Pacific We spoke to Dr Sarthak Das, Chief Executive Officer of the Asia Pacific Leaders Malaria Alliance (APLMA), about the region’s progress towards malaria eradication and the organisation’s priorities, now that its target date for a malaria-free Asia Pacific is just eight years away. … if you compare [malaria] to other…